Restoring the biological activity of crizanlizumab at physiological conditions through a pH-dependent aspartic acid isomerization reaction

• Main Authors: Fabian Bickel (Author), François Griaud (Author), Wolfram Kern (Author), Frieder Kroener (Author), Manuela Gritsch (Author), Jérôme Dayer (Author), Samuel Barteau (Author), Blandine Denefeld (Author), Chi- (Author), Manuel Lang (Author), Izabela Slupska-Muanza (Author), Carla Schmidt (Author), Matthias Berg (Author), Jürgen Sigg (Author), Lina Boado (Author), Dirk Chelius (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACTIn this study, we report the isomerization of an aspartic acid residue in the complementarity-determining region (CDR) of crizanlizumab as a major degradation pathway. The succinimide intermediate and iso-aspartic acid degradation products were successfully isolated by ion exchange chromatog...